High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites
Journal article published in 2019 by
Suraya Elfrink,
Charlotte M. de Winde 
,
Michiel van den Brand ,
Madeleine Berendsen,
Margaretha G. M. Roemer,
Frank Arnold ,
Luuk Janssen,
Alie van der Schaaf,
Erik Jansen,
Patricia J. T. A. Groenen ,
Astrid Eijkelenboom ,
Wendy Stevens,
Corine J. Hess,
J. Han van Krieken ,
Joost S. P. Vermaat
and other authors.
,
Michiel van den Brand ,
Madeleine Berendsen,
Margaretha G. M. Roemer,
Frank Arnold ,
Luuk Janssen,
Alie van der Schaaf,
Erik Jansen,
Patricia J. T. A. Groenen ,
Astrid Eijkelenboom ,
Wendy Stevens,
Corine J. Hess,
J. Han van Krieken ,
Joost S. P. Vermaat
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Loss-of-function mutations in CD37 occur predominantly in diffuse large B-cell lymphoma at immune-privileged sites. CD37-mutated lymphoma B cells show impaired CD37 cell-surface localization, which may have implications for anti-CD37 therapies.